Radiotherapy for thyroid-associated orbitopathy

Kahaly, G.; Hp, Roesler; Kutzner, J; Pitz, Susanne; Müller‐Forell, Wibke; Beyer, J; Mann, Wolf J.

doi:10.1055/s-0029-1212186

Cited by 19 publications

(12 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At our institution, intravenous steroids were usually administered during 12 consecutive weeks (cumulative dose 4.5 g) in clinically active, moderate-to-severe TAO (22,23), whereas in patients with sight-threatening TAO higher doses were given (24). Low dose orbital radiotherapy (with or without additional oral steroids) was performed during 10 weeks with single doses of one Gray per week (25,26) in patients with ocular motility disturbances and clinically active moderate-tosevere TAO.…”

Section: Ophthalmic Assessmentmentioning

confidence: 99%

Prevalence, Phenotype, and Psychosocial Well-Being in Euthyroid/Hypothyroid Thyroid-Associated Orbitopathy

Ponto

Binder

Diana

et al. 2015

Thyroid

View full text Add to dashboard Cite

show abstract

Section: Ophthalmic Assessmentmentioning

confidence: 99%

Prevalence, Phenotype, and Psychosocial Well-Being in Euthyroid/Hypothyroid Thyroid-Associated Orbitopathy

Ponto

Binder

Diana

et al. 2015

Thyroid

View full text Add to dashboard Cite

show abstract

“…The rationale for the use of radiotherapy for TAO resides both in its nonspecific anti-inflammatory effect and in the high radiosensitivity of lymphocytes infiltrating the orbit. [43] Orbital radiotherapy is effective in patients who have active eye disease with recent progression. Patients with inactive GO do not respond to irradiation.…”

Section: Treatmentmentioning

confidence: 99%

Thyroid associated orbitopathy

Maheshwari

Weis

2012

Indian J Ophthalmol

View full text Add to dashboard Cite

Thyroid associated orbitopathy, also known as Graves’ orbitopathy, is typically a self-limiting autoimmune process associated with dysthyroid states. The clinical presentation may vary from very mild disease to severe irreversible sight-threatening complications. Despite ongoing basic science and clinical research, the pathogenesis and highly effective therapeutic strategies remain elusive. The present article reviews the pathophysiology, clinical presentation, and management of this common, yet poorly understood disease, which remains a challenge to the ophthalmologist.

show abstract

“…Orbital radiotherapy Orbital lymphocytes are sensitive to radiotherapy, 43 and low-dose orbital radiotherapy, while not used as monotherapy for acute TED, is a wellestablished adjunctive treatment, 45 and is particularly effective in improving muscle motility during active disease. 46 Although a typical radiotherapy dose is 20 Gy, given in 10 fractions of 2 Gy, lower doses may be equally as effective.…”

Section: Moderate To Severe Tedmentioning

confidence: 99%